Serum Adropin Levels Are Reduced in Adult Patients with Nonalcoholic Fatty Liver Disease
Objectives: Adropin is a novel marker of metabolic syndrome and insulin resistance. The aim of this study was to explore the association of serum adropin levels with hepatosteatosis among adult patients. Materials and Methods: Serum biochemical parameters including liver and renal function tests, in...
Saved in:
| Published in | Medical principles and practice Vol. 28; no. 5; pp. 463 - 469 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Basel, Switzerland
S. Karger AG
01.09.2019
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Objectives: Adropin is a novel marker of metabolic syndrome and insulin resistance. The aim of this study was to explore the association of serum adropin levels with hepatosteatosis among adult patients. Materials and Methods: Serum biochemical parameters including liver and renal function tests, insulin levels, and serum adropin levels were compared between adult patients with nonalcoholic fatty liver disease (NAFLD) and healthy control cases. Results: A total of 51 patients with a mean age of 37.9 ± 9.96 years diagnosed with grade 2–3 hepatosteatosis and 30 healthy control cases with a mean age of 34.8 ± 9.5 years were included in the study. Serum adropin levels in the NAFLD group were statistically significantly lower than in the control cases (588.4 ± 261.0 vs. 894.2 ± 301.2, respectively; p < 0.001). The study participants were further subdivided into 2 groups as patients with (n = 35) or without (n = 46) insulin resistance using the serum homeostatic model of assessment-insulin resistance (HOMA-IR). Serum adropin levels were statistically significantly lower in patients with insulin resistance (p < 0.01). There was a negative correlation between adropin levels and serum insulin, HOMA-IR, urea, gamma-glutamyl transferase, total cholesterol, and triglyceride levels. Conclusion: We observed a decrease in serum adropin levels among adult patients with NAFLD. We also found lower levels of serum adropin in patients with insulin resistance, supporting previous data in the literature. Studies investigating the association of adropin levels with other inflammatory parameters are warranted to define its exact role in the pathogenesis of hepatosteatosis. |
|---|---|
| AbstractList | Objectives: Adropin is a novel marker of metabolic syndrome and insulin resistance. The aim of this study was to explore the association of serum adropin levels with hepatosteatosis among adult patients. Materials and Methods: Serum biochemical parameters including liver and renal function tests, insulin levels, and serum adropin levels were compared between adult patients with nonalcoholic fatty liver disease (NAFLD) and healthy control cases. Results: A total of 51 patients with a mean age of 37.9 ± 9.96 years diagnosed with grade 2–3 hepatosteatosis and 30 healthy control cases with a mean age of 34.8 ± 9.5 years were included in the study. Serum adropin levels in the NAFLD group were statistically significantly lower than in the control cases (588.4 ± 261.0 vs. 894.2 ± 301.2, respectively; p < 0.001). The study participants were further subdivided into 2 groups as patients with (n = 35) or without (n = 46) insulin resistance using the serum homeostatic model of assessment-insulin resistance (HOMA-IR). Serum adropin levels were statistically significantly lower in patients with insulin resistance (p < 0.01). There was a negative correlation between adropin levels and serum insulin, HOMA-IR, urea, gamma-glutamyl transferase, total cholesterol, and triglyceride levels. Conclusion: We observed a decrease in serum adropin levels among adult patients with NAFLD. We also found lower levels of serum adropin in patients with insulin resistance, supporting previous data in the literature. Studies investigating the association of adropin levels with other inflammatory parameters are warranted to define its exact role in the pathogenesis of hepatosteatosis. Adropin is a novel marker of metabolic syndrome and insulin resistance. The aim of this study was to explore the association of serum adropin levels with hepatosteatosis among adult patients. Serum biochemical parameters including liver and renal function tests, insulin levels, and serum adropin levels were compared between adult patients with nonalcoholic fatty liver disease (NAFLD) and healthy control cases. A total of 51 patients with a mean age of 37.9 ± 9.96 years diagnosed with grade 2-3 hepatosteatosis and 30 healthy control cases with a mean age of 34.8 ± 9.5 years were included in the study. Serum adropin levels in the NAFLD group were statistically significantly lower than in the control cases (588.4 ± 261.0 vs. 894.2 ± 301.2, respectively; p < 0.001). The study participants were further subdivided into 2 groups as patients with (n = 35) or without (n = 46) insulin resistance using the serum homeostatic model of assessment-insulin resistance (HOMA-IR). Serum adropin levels were statistically significantly lower in patients with insulin resistance (p < 0.01). There was a negative correlation between adropin levels and serum insulin, HOMA-IR, urea, gamma-glutamyl transferase, total cholesterol, and triglyceride levels. We observed a decrease in serum adropin levels among adult patients with NAFLD. We also found lower levels of serum adropin in patients with insulin resistance, supporting previous data in the literature. Studies investigating the association of adropin levels with other inflammatory parameters are warranted to define its exact role in the pathogenesis of hepatosteatosis. Adropin is a novel marker of metabolic syndrome and insulin resistance. The aim of this study was to explore the association of serum adropin levels with hepatosteatosis among adult patients.OBJECTIVESAdropin is a novel marker of metabolic syndrome and insulin resistance. The aim of this study was to explore the association of serum adropin levels with hepatosteatosis among adult patients.Serum biochemical parameters including liver and renal function tests, insulin levels, and serum adropin levels were compared between adult patients with nonalcoholic fatty liver disease (NAFLD) and healthy control cases.MATERIALS AND METHODSSerum biochemical parameters including liver and renal function tests, insulin levels, and serum adropin levels were compared between adult patients with nonalcoholic fatty liver disease (NAFLD) and healthy control cases.A total of 51 patients with a mean age of 37.9 ± 9.96 years diagnosed with grade 2-3 hepatosteatosis and 30 healthy control cases with a mean age of 34.8 ± 9.5 years were included in the study. Serum adropin levels in the NAFLD group were statistically significantly lower than in the control cases (588.4 ± 261.0 vs. 894.2 ± 301.2, respectively; p < 0.001). The study participants were further subdivided into 2 groups as patients with (n = 35) or without (n = 46) insulin resistance using the serum homeostatic model of assessment-insulin resistance (HOMA-IR). Serum adropin levels were statistically significantly lower in patients with insulin resistance (p < 0.01). There was a negative correlation between adropin levels and serum insulin, HOMA-IR, urea, gamma-glutamyl transferase, total cholesterol, and triglyceride levels.RESULTSA total of 51 patients with a mean age of 37.9 ± 9.96 years diagnosed with grade 2-3 hepatosteatosis and 30 healthy control cases with a mean age of 34.8 ± 9.5 years were included in the study. Serum adropin levels in the NAFLD group were statistically significantly lower than in the control cases (588.4 ± 261.0 vs. 894.2 ± 301.2, respectively; p < 0.001). The study participants were further subdivided into 2 groups as patients with (n = 35) or without (n = 46) insulin resistance using the serum homeostatic model of assessment-insulin resistance (HOMA-IR). Serum adropin levels were statistically significantly lower in patients with insulin resistance (p < 0.01). There was a negative correlation between adropin levels and serum insulin, HOMA-IR, urea, gamma-glutamyl transferase, total cholesterol, and triglyceride levels.We observed a decrease in serum adropin levels among adult patients with NAFLD. We also found lower levels of serum adropin in patients with insulin resistance, supporting previous data in the literature. Studies investigating the association of adropin levels with other inflammatory parameters are warranted to define its exact role in the pathogenesis of hepatosteatosis.CONCLUSIONWe observed a decrease in serum adropin levels among adult patients with NAFLD. We also found lower levels of serum adropin in patients with insulin resistance, supporting previous data in the literature. Studies investigating the association of adropin levels with other inflammatory parameters are warranted to define its exact role in the pathogenesis of hepatosteatosis. |
| Author | Eruzun, Hasan Arman, Yücel Akarsu, Murat Özcan, Mustafa Tükek, Tufan Dikker, Okan Kutlu, Yasin Aydın Yoldemir, Şengül Kutlu, Orkide Altun, Özgür Aktaş, Şerife Toprak, İlkim Deniz Özgün Çil, Eylem Toprak, Zeki Kırna, Kerem Özsoy, Neslihan |
| AuthorAffiliation | b Medical Biochemistry Department, Okmeydanı Training and Research Hospital, Istanbul, Turkey f Internal Medicine Department, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey a Internal Medicine Department, Okmeydanı Training and Research Hospital, Istanbul, Turkey c Internal Medicine Department, Umraniye Training and Research Hospital, Istanbul, Turkey d Internal Medicine Department, Haseki Training and Research Hospital, Istanbul, Turkey e Nephrology Department, Bakırkoy Dr. Sadı Konuk Training and Research Hospital, Istanbul, Turkey |
| AuthorAffiliation_xml | – name: f Internal Medicine Department, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey – name: c Internal Medicine Department, Umraniye Training and Research Hospital, Istanbul, Turkey – name: e Nephrology Department, Bakırkoy Dr. Sadı Konuk Training and Research Hospital, Istanbul, Turkey – name: a Internal Medicine Department, Okmeydanı Training and Research Hospital, Istanbul, Turkey – name: b Medical Biochemistry Department, Okmeydanı Training and Research Hospital, Istanbul, Turkey – name: d Internal Medicine Department, Haseki Training and Research Hospital, Istanbul, Turkey |
| Author_xml | – sequence: 1 givenname: Orkide surname: Kutlu fullname: Kutlu, Orkide – sequence: 2 givenname: Özgür surname: Altun fullname: Altun, Özgür – sequence: 3 givenname: Okan surname: Dikker fullname: Dikker, Okan – sequence: 4 givenname: Şerife orcidid: 0000-0002-0784-7146 surname: Aktaş fullname: Aktaş, Şerife – sequence: 5 givenname: Neslihan surname: Özsoy fullname: Özsoy, Neslihan – sequence: 6 givenname: Yücel surname: Arman fullname: Arman, Yücel – sequence: 7 givenname: Eylem surname: Özgün Çil fullname: Özgün Çil, Eylem – sequence: 8 givenname: Mustafa surname: Özcan fullname: Özcan, Mustafa – sequence: 9 givenname: Şengül surname: Aydın Yoldemir fullname: Aydın Yoldemir, Şengül – sequence: 10 givenname: Murat surname: Akarsu fullname: Akarsu, Murat – sequence: 11 givenname: İlkim Deniz surname: Toprak fullname: Toprak, İlkim Deniz – sequence: 12 givenname: Kerem surname: Kırna fullname: Kırna, Kerem – sequence: 13 givenname: Yasin surname: Kutlu fullname: Kutlu, Yasin – sequence: 14 givenname: Zeki surname: Toprak fullname: Toprak, Zeki – sequence: 15 givenname: Hasan orcidid: 0000-0003-0355-1820 surname: Eruzun fullname: Eruzun, Hasan email: hasaneruzun@gmail.com – sequence: 16 givenname: Tufan surname: Tükek fullname: Tükek, Tufan |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/30995640$$D View this record in MEDLINE/PubMed |
| BookMark | eNptkc1vEzEUxC1URD_gwB0hS1zgsO2zHe96L5WiQlukABH0wM3y2m8bl8062LtB_e9xlBDRqidb9s_zxjPH5KAPPRLymsEpY7I-AwAJwKB8Ro7YhIsCmGQHeQ-MFZWs2CE5TukuY0oIeEEOBdS1LCdwRH7-wDgu6dTFsPI9neEau0SnEel3dKNFR_Pp1I3dQOdm8NgPif7xw4J-Db3pbFiEzlt6aYbhns78GiP96BOahC_J89Z0CV_t1hNyc_np5uK6mH27-nwxnRVWsnoo8gSYuLbkYEFWTnCjoBGOO9kqUavaILOK86ZE5UTjWqO4s4Y3jWQGZCtOyPlWdjU2S3Q2G4ym06volybe62C8fnjT-4W-DWtdVhWDimeB9zuBGH6PmAa99Mli15kew5g054wJLiquMvruEXoXxphjyJTIFShVcZmpt_872lv5l3kGPmwBG0NKEds9wkBv-tT7PjN79oi1fsg9hM1nfPfki53JXybeYtxrf5nPt4ReuU1sb56kdiJ_AWO5tdM |
| CitedBy_id | crossref_primary_10_1038_s41374_020_00508_y crossref_primary_10_2147_DMSO_S243755 crossref_primary_10_4103_jasmr_jasmr_30_20 crossref_primary_10_58252_artukluder_1243870 crossref_primary_10_1016_j_liver_2024_100228 crossref_primary_10_1152_ajpheart_00385_2022 crossref_primary_10_3389_fphys_2021_696163 crossref_primary_10_3389_fphys_2024_1435448 crossref_primary_10_1159_000502106 crossref_primary_10_1111_obr_13108 crossref_primary_10_1002_jpn3_12423 crossref_primary_10_3892_ijmm_2024_5414 crossref_primary_10_1038_s42255_019_0145_5 crossref_primary_10_1186_s12902_023_01327_0 crossref_primary_10_1089_met_2021_0015 crossref_primary_10_3390_biom14121613 crossref_primary_10_3389_fphys_2021_692642 crossref_primary_10_2174_0115701646301720240830070246 crossref_primary_10_1007_s00592_023_02082_3 crossref_primary_10_3390_biology10050413 crossref_primary_10_1016_j_fshw_2022_06_002 crossref_primary_10_1152_ajpheart_00449_2020 crossref_primary_10_1159_000502039 crossref_primary_10_3389_fimmu_2025_1482308 crossref_primary_10_3390_medicina61010038 crossref_primary_10_28982_josam_859388 crossref_primary_10_1016_j_freeradbiomed_2020_08_005 crossref_primary_10_3390_molecules25030549 |
| Cites_doi | 10.1152/ajpendo.90920.2008 10.1002/oby.20631 10.1155/2016/6038261 10.5604/17322693.1216271 10.4103/2231-4040.90879 10.1016/j.cmet.2008.10.011 10.1016/j.alcohol.2004.07.007 10.1016/j.molmet.2015.01.005 10.1007/s40618-016-0453-5 10.1053/j.gastro.2010.09.038 10.4149/BLL_2016_020 10.3390/nu9040387 10.1146/annurev-physiol-021115-105331 10.1016/j.cgh.2015.07.029 10.1515/cclm-2013-0844 10.1515/jpem-2013-0296 10.1530/JME-15-0207 10.2214/ajr.145.4.753 10.2310/JIM.0000000000000003 10.2337/diabetes.53.8.2060 10.1161/01.CIR.0000089191.72957.ED 10.1007/s11010-013-1660-4 10.3748/wjg.v22.i31.7006 10.1038/oby.2012.31 10.1002/hep.25772 10.1161/CIRCULATIONAHA.109.931782 10.1210/jc.2012-2194 10.1016/j.orcp.2017.03.001 10.1002/hep.24001 |
| ContentType | Journal Article |
| Copyright | 2019 The Author(s) Published by S. Karger AG, Basel 2019 The Author(s) Published by S. Karger AG, Basel. Copyright © 2019 by S. Karger AG, Basel 2019 |
| Copyright_xml | – notice: 2019 The Author(s) Published by S. Karger AG, Basel – notice: 2019 The Author(s) Published by S. Karger AG, Basel. – notice: Copyright © 2019 by S. Karger AG, Basel 2019 |
| DBID | M-- AAYXX CITATION NPM 3V. 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA BENPR CCPQU FYUFA GHDGH K9. M0S M1P PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI 7X8 5PM |
| DOI | 10.1159/000500106 |
| DatabaseName | Karger Open Access Journals CrossRef PubMed ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central ProQuest One Community College Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection Medical Database ProQuest Central Premium ProQuest One Academic (New) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef PubMed ProQuest One Academic Middle East (New) ProQuest One Academic Eastern Edition ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Central ProQuest Health & Medical Complete ProQuest Health & Medical Research Collection Health Research Premium Collection ProQuest Medical Library ProQuest One Academic UKI Edition Health and Medicine Complete (Alumni Edition) Health & Medical Research Collection ProQuest Central (New) ProQuest One Academic ProQuest One Academic (New) ProQuest Medical Library (Alumni) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | ProQuest One Academic Middle East (New) PubMed CrossRef MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: M-- name: Karger Open Access Journals url: https://www.karger.com/OpenAccess sourceTypes: Enrichment Source Publisher – sequence: 3 dbid: 7X7 name: Health & Medical Collection url: https://search.proquest.com/healthcomplete sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1423-0151 |
| EndPage | 469 |
| ExternalDocumentID | PMC6771072 30995640 10_1159_000500106 500106 |
| Genre | Journal Article |
| GroupedDBID | --- 0R~ 0~B 30W 326 36B 3O. 3V. 4.4 53G 5GY 7X7 88E 8FI 8FJ 8UI AAWTL AAYIC ABPAZ ABUWG ACGFS ADBBV AENEX AEYAO AFKRA AHMBA ALDHI ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS AZPMC BAWUL BCNDV BENPR BPHCQ BVXVI CCPQU CS3 CYUIP DIK DU5 E0A E3Z EBS EJD EMB EMOBN F5P FB. FYUFA GROUPED_DOAJ HMCUK HYE HZ~ IAO IHR KUZGX M-- M1P MK0 O1H O9- OK1 P2P PQQKQ PROAC PSQYO RKO RNS RPM SV3 UJ6 UKHRP AAYXX ABBTS ABWCG ACQXL ADAGL AFJJK AFSIO AHFRZ AIOBO CAG CITATION COF ITC PHGZM PHGZT RIG RXVBD TR2 NPM 7XB 8FK K9. PJZUB PKEHL PPXIY PQEST PQUKI 7X8 5PM |
| ID | FETCH-LOGICAL-c519t-ced04df620c057d32a80b3d2d5f83989ae1c822b6e8d3bdfa82dca2bb51a05f3 |
| IEDL.DBID | M-- |
| ISSN | 1011-7571 1423-0151 |
| IngestDate | Thu Aug 21 18:32:19 EDT 2025 Fri Jul 11 12:30:13 EDT 2025 Fri Jul 25 21:11:02 EDT 2025 Thu Apr 03 07:08:08 EDT 2025 Tue Jul 01 05:01:32 EDT 2025 Thu Apr 24 23:07:09 EDT 2025 Thu Aug 29 12:04:35 EDT 2024 Thu Sep 05 18:04:23 EDT 2024 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 5 |
| Keywords | Adropin Hepatosteatosis Liver disease |
| Language | English |
| License | This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC). Usage and distribution for commercial purposes requires written permission. https://creativecommons.org/licenses/by-nc/4.0 2019 The Author(s) Published by S. Karger AG, Basel. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c519t-ced04df620c057d32a80b3d2d5f83989ae1c822b6e8d3bdfa82dca2bb51a05f3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| ORCID | 0000-0002-0784-7146 0000-0003-0355-1820 |
| OpenAccessLink | https://karger.com/doi/10.1159/000500106 |
| PMID | 30995640 |
| PQID | 2300588725 |
| PQPubID | 2047984 |
| PageCount | 7 |
| ParticipantIDs | crossref_primary_10_1159_000500106 proquest_miscellaneous_2211323728 crossref_citationtrail_10_1159_000500106 proquest_journals_2300588725 karger_primary_500106 pubmedcentral_primary_oai_pubmedcentral_nih_gov_6771072 pubmed_primary_30995640 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2019-09-01 |
| PublicationDateYYYYMMDD | 2019-09-01 |
| PublicationDate_xml | – month: 09 year: 2019 text: 2019-09-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | Basel, Switzerland |
| PublicationPlace_xml | – name: Basel, Switzerland – name: Switzerland – name: Basel – name: Allschwilerstrasse 10, P.O. Box · Postfach · Case postale, CH–4009, Basel, Switzerland · Schweiz · Suisse, Phone: +41 61 306 11 11, Fax: +41 61 306 12 34, karger@karger.com |
| PublicationTitle | Medical principles and practice |
| PublicationTitleAlternate | Med Princ Pract |
| PublicationYear | 2019 |
| Publisher | S. Karger AG |
| Publisher_xml | – name: S. Karger AG |
| References | Abenavoli L, Milic N, Di Renzo L, Preveden T, Medić-Stojanoska M, De Lorenzo A. Metabolic aspects of adult patients with nonalcoholic fatty liver disease. World J Gastroenterol. 2016Aug;22(31):7006–16. 10.3748/wjg.v22.i31.7006276100121007-9327 Butler AA, Tam CS, Stanhope KL, Wolfe BM, Ali MR, O’Keeffe M, et al.. Low circulating adropin concentrations with obesity and aging correlate with risk factors for metabolic disease and increase after gastric bypass surgery in humans. J Clin Endocrinol Metab. 2012Oct;97(10):3783–91. 10.1210/jc.2012-2194228726900021-972X Kałużna M, Hoppe K, Schwermer K, Ibrahim AY, Pawlaczyk K, Ziemnicka K. Adropin and irisin levels in relation to nutrition, body composition, and insulin resistance in patients with end-stage renal disease on chronic hemodialysis and peritoneal dialysis. Pol Arch Med Wewn. 2016Jul;126(7-8):474–82.274526720032-3772 Wu L, Fang J, Chen L, Zhao Z, Luo Y, Lin C, et al.. Low serum adropin is associated with coronary atherosclerosis in type 2 diabetic and non-diabetic patients. Clin Chem Lab Med. 2014May;52(5):751–8. 10.1515/cclm-2013-0844243238921434-6621 Lian A, Wu K, Liu T, Jiang N, Jiang Q. Adropin induction of lipoprotein lipase expression in tilapia hepatocytes. J Mol Endocrinol. 2016Jan;56(1):11–22. 10.1530/JME-15-0207264643340952-5041 Baka S, Malamitsi-Puchner A, Briana DD, Boutsikou M, Marmarinos A, Gourgiotis D, et al.. Adropin concentrations in term pregnancies with normal, restricted and increased fetal growth. J Matern Fetal Neonatal Med. 2016;29(15):2403–7.264903871476-4954 Kitade H, Chen G, Ni Y, Ota T. Nonalcoholic fatty liver disease and insulin resistance: new insights and potential new treatments. Nutrients. 2017Apr;9(4):387. 10.3390/nu9040387284200942072-6643 Williams CD, Stengel J, Asike MI, Torres DM, Shaw J, Contreras M, et al.. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology. 2011Jan;140(1):124–31. 10.1053/j.gastro.2010.09.038208584920016-5085 Tilg H, Moschen AR. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology. 2010Nov;52(5):1836–46. 10.1002/hep.24001210384180270-9139 Topuz M, Celik A, Aslantas T, Demir AK, Aydin S, Aydin S. Plasma adropin levels predict endothelial dysfunction like flow-mediated dilatation in patients with type 2 diabetes mellitus. J Investig Med. 2013Dec;61(8):1161–4. 10.2310/JIM.0000000000000003241137361081-5589 Gao S, McMillan RP, Zhu Q, Lopaschuk GD, Hulver MW, Butler AA. Therapeutic effects of adropin on glucose tolerance and substrate utilization in diet-induced obese mice with insulin resistance. Mol Metab. 2015Jan;4(4):310–24. 10.1016/j.molmet.2015.01.005258300942212-8778 Akcilar R, Kocak FE, Simsek H, Akcilar A, Bayat Z, Ece E, et al.. Antidiabetic and hypolipidemic effects of adropinin streoptozotocin-induced type 2 diabetic rats. Bratisl Lek Listy. 2016;117(2):100–5. 10.4149/BLL_2016_020268300410006-9248 Haas JT, Francque S, Staels B. Pathophysiology and mechanisms of nonalcoholic fatty liver disease. Annu Rev Physiol. 2016;78(1):181–205. 10.1146/annurev-physiol-021115-105331266670700066-4278 Verma S, Buchanan MR, Anderson TJ. Endothelial function testing as a biomarker of vascular disease. Circulation. 2003Oct;108(17):2054–9. 10.1161/01.CIR.0000089191.72957.ED145813840009-7322 Mierzwicka A, Bolanowski M. New peptides players in metabolic disorders. Postepy Hig Med Dosw. 2016Aug;70(0):881–6. 10.5604/17322693.1216271275945630032-5449 Ganesh Kumar K, Zhang J, Gao S, Rossi J, McGuinness OP, Halem HH, et al.. Adropin deficiency is associated with increased adiposity and insulin resistance. Obesity (Silver Spring). 2012Jul;20(7):1394–402. 10.1038/oby.2012.31223183151930-7381 Mather KJ, Lteif A, Steinberg HO, Baron AD. Interactions between endothelin and nitric oxide in the regulation of vascular tone in obesity and diabetes. Diabetes. 2004Aug;53(8):2060–6. 10.2337/diabetes.53.8.2060152773860012-1797 Aydin S, Kuloglu T, Aydin S, Eren MN, Yilmaz M, Kalayci M, et al.. Expression of adropin in rat brain, cerebellum, kidneys, heart, liver, and pancreas in streptozotocin-induced diabetes. Mol Cell Biochem. 2013Aug;380(1-2):73–81. 10.1007/s11010-013-1660-4236203400300-8177 Chang JB, Chu NF, Lin FH, Hsu JT, Chen PY. Relationship between plasma adropin levels and body composition and lipid characteristics amongst young adolescents in Taiwan. Obes Res Clin Pract. 2018Jan - Feb;12(1Suppl 2):101–7. 10.1016/j.orcp.2017.03.001283637051871-403X Quinn SF, Gosink BB. Characteristic sonographic signs of hepatic fatty infiltration. AJR Am J Roentgenol. 1985Oct;145(4):753–5. 10.2214/ajr.145.4.75338987840361-803X Lovren F, Pan Y, Quan A, Singh KK, Shukla PC, Gupta M, et al.. Adropin is a novel regulator of endothelial function. Circulation. 2010Sep;122(11Suppl):S185–92. 10.1161/CIRCULATIONAHA.109.931782208379120009-7322 Kumar KG, Trevaskis JL, Lam DD, Sutton GM, Koza RA, Chouljenko VN, et al.. Identification of adropin as a secreted factor linking dietary macronutrient intake with energy homeostasis and lipid metabolism. Cell Metab. 2008Dec;8(6):468–81. 10.1016/j.cmet.2008.10.011190417631550-4131 St-Onge MP, Shechter A, Shlisky J, Tam CS, Gao S, Ravussin E, et al.. Fasting plasma adropin concentrations correlate with fat consumption in human females. Obesity (Silver Spring). 2014Apr;22(4):1056–63. 10.1002/oby.20631241153731930-7381 Loomba R, Abraham M, Unalp A, Wilson L, Lavine J, Doo E, et al.; Nonalcoholic Steatohepatitis Clinical Research Network. Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis. Hepatology. 2012Sep;56(3):943–51. 10.1002/hep.25772225051940270-9139 Tyagi S, Gupta P, Saini AS, Kaushal C, Sharma S. The peroxisome proliferator-activated receptor: A family of nuclear receptors role in various diseases. J Adv Pharm Technol Res. 2011Oct;2(4):236–40. 10.4103/2231-4040.90879222478902231-4040 Hu W, Chen L. Association of serum adropin concentrations with diabetic nephropathy. Mediators Inflamm. 2016;2016:6038261. 10.1155/2016/6038261275469950962-9351 McClain CJ, Mokshagundam SP, Barve SS, Song Z, Hill DB, Chen T, et al.. Mechanisms of non-alcoholic steatohepatitis. Alcohol. 2004Aug;34(1):67–79. 10.1016/j.alcohol.2004.07.007156706680741-8329 Ahmed A, Wong RJ, Harrison SA. Nonalcoholic fatty liver disease review: diagnosis, treatment, and outcomes. Clin Gastroenterol Hepatol. 2015Nov;13(12):2062–70. 10.1016/j.cgh.2015.07.029262260971542-3565 Kume T, Calan M, Yilmaz O, Kocabas GU, Yesil P, Temur M, et al.. A possible connection between tumor necrosis factor alpha and adropin levels in polycystic ovary syndrome. J Endocrinol Invest. 2016Jul;39(7):747–54. 10.1007/s40618-016-0453-5269694610391-4097 Sayın O, Tokgöz Y, Arslan N. Investigation of adropin and leptin levels in pediatric obesity-related nonalcoholic fatty liver disease. J Pediatr Endocrinol Metab. 2014May;27(5-6):479–84. 10.1515/jpem-2013-0296244686000334-018X Wang H, Eckel RH. Lipoprotein lipase: from gene to obesity. Am J Physiol Endocrinol Metab. 2009Aug;297(2):E271–88. 10.1152/ajpendo.90920.2008193185140193-1849 ref13 ref12 ref15 ref14 ref11 ref10 ref2 ref1 ref17 ref16 ref19 ref18 ref24 ref23 ref26 ref25 ref20 ref22 ref21 ref28 ref27 ref29 ref8 ref7 ref9 ref4 ref3 ref6 ref5 31291637 - Med Princ Pract. 2020;29(1):97 31505512 - Med Princ Pract. 2020;29(1):98 |
| References_xml | – reference: Hu W, Chen L. Association of serum adropin concentrations with diabetic nephropathy. Mediators Inflamm. 2016;2016:6038261. 10.1155/2016/6038261275469950962-9351 – reference: Kume T, Calan M, Yilmaz O, Kocabas GU, Yesil P, Temur M, et al.. A possible connection between tumor necrosis factor alpha and adropin levels in polycystic ovary syndrome. J Endocrinol Invest. 2016Jul;39(7):747–54. 10.1007/s40618-016-0453-5269694610391-4097 – reference: Chang JB, Chu NF, Lin FH, Hsu JT, Chen PY. Relationship between plasma adropin levels and body composition and lipid characteristics amongst young adolescents in Taiwan. Obes Res Clin Pract. 2018Jan - Feb;12(1Suppl 2):101–7. 10.1016/j.orcp.2017.03.001283637051871-403X – reference: Kitade H, Chen G, Ni Y, Ota T. Nonalcoholic fatty liver disease and insulin resistance: new insights and potential new treatments. Nutrients. 2017Apr;9(4):387. 10.3390/nu9040387284200942072-6643 – reference: Loomba R, Abraham M, Unalp A, Wilson L, Lavine J, Doo E, et al.; Nonalcoholic Steatohepatitis Clinical Research Network. Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis. Hepatology. 2012Sep;56(3):943–51. 10.1002/hep.25772225051940270-9139 – reference: St-Onge MP, Shechter A, Shlisky J, Tam CS, Gao S, Ravussin E, et al.. Fasting plasma adropin concentrations correlate with fat consumption in human females. Obesity (Silver Spring). 2014Apr;22(4):1056–63. 10.1002/oby.20631241153731930-7381 – reference: Williams CD, Stengel J, Asike MI, Torres DM, Shaw J, Contreras M, et al.. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology. 2011Jan;140(1):124–31. 10.1053/j.gastro.2010.09.038208584920016-5085 – reference: Ahmed A, Wong RJ, Harrison SA. Nonalcoholic fatty liver disease review: diagnosis, treatment, and outcomes. Clin Gastroenterol Hepatol. 2015Nov;13(12):2062–70. 10.1016/j.cgh.2015.07.029262260971542-3565 – reference: Haas JT, Francque S, Staels B. Pathophysiology and mechanisms of nonalcoholic fatty liver disease. Annu Rev Physiol. 2016;78(1):181–205. 10.1146/annurev-physiol-021115-105331266670700066-4278 – reference: Quinn SF, Gosink BB. Characteristic sonographic signs of hepatic fatty infiltration. AJR Am J Roentgenol. 1985Oct;145(4):753–5. 10.2214/ajr.145.4.75338987840361-803X – reference: Lian A, Wu K, Liu T, Jiang N, Jiang Q. Adropin induction of lipoprotein lipase expression in tilapia hepatocytes. J Mol Endocrinol. 2016Jan;56(1):11–22. 10.1530/JME-15-0207264643340952-5041 – reference: Baka S, Malamitsi-Puchner A, Briana DD, Boutsikou M, Marmarinos A, Gourgiotis D, et al.. Adropin concentrations in term pregnancies with normal, restricted and increased fetal growth. J Matern Fetal Neonatal Med. 2016;29(15):2403–7.264903871476-4954 – reference: Ganesh Kumar K, Zhang J, Gao S, Rossi J, McGuinness OP, Halem HH, et al.. Adropin deficiency is associated with increased adiposity and insulin resistance. Obesity (Silver Spring). 2012Jul;20(7):1394–402. 10.1038/oby.2012.31223183151930-7381 – reference: Lovren F, Pan Y, Quan A, Singh KK, Shukla PC, Gupta M, et al.. Adropin is a novel regulator of endothelial function. Circulation. 2010Sep;122(11Suppl):S185–92. 10.1161/CIRCULATIONAHA.109.931782208379120009-7322 – reference: McClain CJ, Mokshagundam SP, Barve SS, Song Z, Hill DB, Chen T, et al.. Mechanisms of non-alcoholic steatohepatitis. Alcohol. 2004Aug;34(1):67–79. 10.1016/j.alcohol.2004.07.007156706680741-8329 – reference: Butler AA, Tam CS, Stanhope KL, Wolfe BM, Ali MR, O’Keeffe M, et al.. Low circulating adropin concentrations with obesity and aging correlate with risk factors for metabolic disease and increase after gastric bypass surgery in humans. J Clin Endocrinol Metab. 2012Oct;97(10):3783–91. 10.1210/jc.2012-2194228726900021-972X – reference: Verma S, Buchanan MR, Anderson TJ. Endothelial function testing as a biomarker of vascular disease. Circulation. 2003Oct;108(17):2054–9. 10.1161/01.CIR.0000089191.72957.ED145813840009-7322 – reference: Sayın O, Tokgöz Y, Arslan N. Investigation of adropin and leptin levels in pediatric obesity-related nonalcoholic fatty liver disease. J Pediatr Endocrinol Metab. 2014May;27(5-6):479–84. 10.1515/jpem-2013-0296244686000334-018X – reference: Gao S, McMillan RP, Zhu Q, Lopaschuk GD, Hulver MW, Butler AA. Therapeutic effects of adropin on glucose tolerance and substrate utilization in diet-induced obese mice with insulin resistance. Mol Metab. 2015Jan;4(4):310–24. 10.1016/j.molmet.2015.01.005258300942212-8778 – reference: Topuz M, Celik A, Aslantas T, Demir AK, Aydin S, Aydin S. Plasma adropin levels predict endothelial dysfunction like flow-mediated dilatation in patients with type 2 diabetes mellitus. J Investig Med. 2013Dec;61(8):1161–4. 10.2310/JIM.0000000000000003241137361081-5589 – reference: Tyagi S, Gupta P, Saini AS, Kaushal C, Sharma S. The peroxisome proliferator-activated receptor: A family of nuclear receptors role in various diseases. J Adv Pharm Technol Res. 2011Oct;2(4):236–40. 10.4103/2231-4040.90879222478902231-4040 – reference: Tilg H, Moschen AR. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology. 2010Nov;52(5):1836–46. 10.1002/hep.24001210384180270-9139 – reference: Kumar KG, Trevaskis JL, Lam DD, Sutton GM, Koza RA, Chouljenko VN, et al.. Identification of adropin as a secreted factor linking dietary macronutrient intake with energy homeostasis and lipid metabolism. Cell Metab. 2008Dec;8(6):468–81. 10.1016/j.cmet.2008.10.011190417631550-4131 – reference: Mather KJ, Lteif A, Steinberg HO, Baron AD. Interactions between endothelin and nitric oxide in the regulation of vascular tone in obesity and diabetes. Diabetes. 2004Aug;53(8):2060–6. 10.2337/diabetes.53.8.2060152773860012-1797 – reference: Abenavoli L, Milic N, Di Renzo L, Preveden T, Medić-Stojanoska M, De Lorenzo A. Metabolic aspects of adult patients with nonalcoholic fatty liver disease. World J Gastroenterol. 2016Aug;22(31):7006–16. 10.3748/wjg.v22.i31.7006276100121007-9327 – reference: Aydin S, Kuloglu T, Aydin S, Eren MN, Yilmaz M, Kalayci M, et al.. Expression of adropin in rat brain, cerebellum, kidneys, heart, liver, and pancreas in streptozotocin-induced diabetes. Mol Cell Biochem. 2013Aug;380(1-2):73–81. 10.1007/s11010-013-1660-4236203400300-8177 – reference: Mierzwicka A, Bolanowski M. New peptides players in metabolic disorders. Postepy Hig Med Dosw. 2016Aug;70(0):881–6. 10.5604/17322693.1216271275945630032-5449 – reference: Kałużna M, Hoppe K, Schwermer K, Ibrahim AY, Pawlaczyk K, Ziemnicka K. Adropin and irisin levels in relation to nutrition, body composition, and insulin resistance in patients with end-stage renal disease on chronic hemodialysis and peritoneal dialysis. Pol Arch Med Wewn. 2016Jul;126(7-8):474–82.274526720032-3772 – reference: Wu L, Fang J, Chen L, Zhao Z, Luo Y, Lin C, et al.. Low serum adropin is associated with coronary atherosclerosis in type 2 diabetic and non-diabetic patients. Clin Chem Lab Med. 2014May;52(5):751–8. 10.1515/cclm-2013-0844243238921434-6621 – reference: Akcilar R, Kocak FE, Simsek H, Akcilar A, Bayat Z, Ece E, et al.. Antidiabetic and hypolipidemic effects of adropinin streoptozotocin-induced type 2 diabetic rats. Bratisl Lek Listy. 2016;117(2):100–5. 10.4149/BLL_2016_020268300410006-9248 – reference: Wang H, Eckel RH. Lipoprotein lipase: from gene to obesity. Am J Physiol Endocrinol Metab. 2009Aug;297(2):E271–88. 10.1152/ajpendo.90920.2008193185140193-1849 – ident: ref21 doi: 10.1152/ajpendo.90920.2008 – ident: ref26 doi: 10.1002/oby.20631 – ident: ref11 doi: 10.1155/2016/6038261 – ident: ref19 doi: 10.5604/17322693.1216271 – ident: ref25 doi: 10.4103/2231-4040.90879 – ident: ref7 doi: 10.1016/j.cmet.2008.10.011 – ident: ref4 doi: 10.1016/j.alcohol.2004.07.007 – ident: ref10 doi: 10.1016/j.molmet.2015.01.005 – ident: ref14 doi: 10.1007/s40618-016-0453-5 – ident: ref2 doi: 10.1053/j.gastro.2010.09.038 – ident: ref28 doi: 10.4149/BLL_2016_020 – ident: ref1 doi: 10.3390/nu9040387 – ident: ref6 doi: 10.1146/annurev-physiol-021115-105331 – ident: ref3 doi: 10.1016/j.cgh.2015.07.029 – ident: ref12 doi: 10.1515/cclm-2013-0844 – ident: ref15 doi: 10.1515/jpem-2013-0296 – ident: ref20 doi: 10.1530/JME-15-0207 – ident: ref16 doi: 10.2214/ajr.145.4.753 – ident: ref13 doi: 10.2310/JIM.0000000000000003 – ident: ref23 doi: 10.2337/diabetes.53.8.2060 – ident: ref22 doi: 10.1161/01.CIR.0000089191.72957.ED – ident: ref9 doi: 10.1007/s11010-013-1660-4 – ident: ref17 doi: 10.3748/wjg.v22.i31.7006 – ident: ref24 doi: 10.1038/oby.2012.31 – ident: ref18 doi: 10.1002/hep.25772 – ident: ref8 doi: 10.1161/CIRCULATIONAHA.109.931782 – ident: ref27 doi: 10.1210/jc.2012-2194 – ident: ref29 doi: 10.1016/j.orcp.2017.03.001 – ident: ref5 doi: 10.1002/hep.24001 – reference: 31291637 - Med Princ Pract. 2020;29(1):97 – reference: 31505512 - Med Princ Pract. 2020;29(1):98 |
| SSID | ssj0008330 |
| Score | 2.3260548 |
| Snippet | Objectives: Adropin is a novel marker of metabolic syndrome and insulin resistance. The aim of this study was to explore the association of serum adropin... Adropin is a novel marker of metabolic syndrome and insulin resistance. The aim of this study was to explore the association of serum adropin levels with... |
| SourceID | pubmedcentral proquest pubmed crossref karger |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 463 |
| SubjectTerms | Body composition Cholesterol Chronic illnesses Diabetes Family medical history Fasting Fatty acids Fatty liver Females Gastrointestinal surgery Homeostasis Hypertension Insulin resistance Laboratories Lipoproteins Liver diseases Metabolism Obesity Original Paper Pediatrics Peptides Ultrasonic imaging Weight control |
| SummonAdditionalLinks | – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwEB5BQYhLxaOUlIIM4sDFIrGTODmhFbCqULdaoSLtLfJTVJTssps98O-ZSbyBrSqunlESZTz2N57xNwBvvc69Mnng3krJc9wjuAlaca9DoRRC4tLSecfsojz7ln9ZFIt44LaJZZW7NbFfqN3S0hn5e0G86ugRoviw-sWpaxRlV2MLjbtwj6jLqKRLLcaAC9GFHNgIsoyrQmWRWQh38L6XXR8P7e1H939Q-fX6NrR5s2jyn11o-ggOI3xkk8Hej-GOb5_Ag1lMkD-FBfr-9iebuDVdhGLnVBK0QXXPvhJHq3cMRyfEucHmA6PqhtFRLLsgRN53y72ybKq77jc7p5IN9mnI4BzB5fTz5cczHpsncIugrOP4xDR3oRSpRUjmpNBVaqQTrgiIiapa-8wiODClr5w0LuhKOKuFMUWm0yLIZ3DQLlv_HFioS6-1rmq6heqNq_qoNnd17bUxSiTwbvcHGxuJxam_xXXTBxhF3Yw_O4E3o-pqYNO4TeloMMOoshs_vTE-m88HUbNyAcU7ozXRDzfN31mTwOtRjB5EaRHd-uUWdTAGlkIqUSVwPNh4fINM6eZvniag9qw_KhA7976kvfres3SXCsGbEif__6wX8BAhWKxaO4WDbr31LxHmdOZVP5f_AMWE-0Q priority: 102 providerName: ProQuest |
| Title | Serum Adropin Levels Are Reduced in Adult Patients with Nonalcoholic Fatty Liver Disease |
| URI | https://karger.com/doi/10.1159/000500106 https://www.ncbi.nlm.nih.gov/pubmed/30995640 https://www.proquest.com/docview/2300588725 https://www.proquest.com/docview/2211323728 https://pubmed.ncbi.nlm.nih.gov/PMC6771072 |
| Volume | 28 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwdV1Nb9QwEB3RFlW9ID4KBMrKIA5cLCV2EifHBbqqUHe1qoq0t8iObVEV0qqbPfDvmbGzUbcqV88kUTy25814_Azw2encKZN77lopeY4-ghuvFXfaF0ohJC5bynfMF-XZz_zHqlgN-Q46C3NN9c-BGnXkFkCHG66eC-HLHhxgHCWJJX_O-bjmVlJG3oEs46pQ2cAhtPPoERzKlA5yUqLjnhN6Gr_5GMR8WCl5z_XMnsOzATOyaTTyC3jiupdwOB92xV_BCif85g-b2js6_cTOqQ5ojeqOXRAxq7MMW6dEtMGWkUZ1zSj_yhYEw8MVuVctm-m-_8vOqU6DfY_bNsdwOTu9_HbGhxsTeItIrOf4xjS3vhRpizjMSqGr1EgrbOERCFW1dlmLiMCUrrLSWK8rYVstjCkynRZevob97qZzb4H5unRa66qmo6fO2CqEsrmta6eNUSKBL9sebNqBTZwutfjdhKiiqJux3xP4NKreRgqNx5SOoxlGlW37yYP2-XIZRc2t9SjeGq0ZJt-6EUTBj4unKBL4OIpx2tBeiO7czQZ1MPCVQipRJfAm2nj8wnaUJKB2rD8qECX3rqS7-hWouUuFiE2Jd__5m_dwhIBrqFE7gf3-buM-IKjpzQT21EpN4ODr6WJ5MQmpgUkY4_8ALEXzKA |
| linkProvider | Karger AG |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwED-NDgEviI8BgQEGgcSLtcRO4uQBocJWdaytqqlIfYv8FTFtpKVNhfZH8T9yzhd0mnjbq31KK5_v_Dvf-XcA76wMrVBhTq3mnIZ4RlCVS0GtzCMhEBLH2t13jCfx8Fv4dR7Nd-B3-xbGlVW2PrFy1Gah3R35AXO86mgRLPq0_Eld1yiXXW1baNTb4sRe_sKQbf3x-BD1-56xwdHsy5A2XQWoRrRSUm2NH5o8Zr5GrGI4k4mvuGEmyhEsJKm0gcZTU8U2MVyZXCbMaMmUigLpRznHz96C3ZBjJNOD3c9Hk-lp5_oTzmv6gyCgIhJBQ2WEkKFqnlcFYFsH4O1zV--9ug7eXq3S_OfYGzyA-w1eJf16gz2EHVs8gjvjJiP_GObobDY_SN-s3MsrMnI1SGsUt-TUkcJaQ3C070g-yLSmcF0Td_dLJi4EqNrznmkykGV5SUauRoQc1imjPZjdxLo-gV6xKOwzIHkaWyllkrpnr1aZpAqjQ5OmViolmAcf2hXMdMNk7hpqXGRVRBOlWbfYHrztRJc1fcd1Qnu1GjqRdnz_yvh4Oq2nsqXJcbpVWtYY_jr7u009eNNNo8m6PIws7GKDMhh0c8YFSzx4Wuu4-wXuu6fGoe-B2NJ-J-DowLdnirPvFS14LBAtCvb8_3_rNdwdzsajbHQ8OXkB9xD_NSVz-9ArVxv7EjFWqV41O5tAdsO29AcBDjqo |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9NAEB6VgqpeEI8ChgILAomLVXvX9toHhCJC1NIkilCRcrP2ZVFRnJA4Qv1p_Dtm_IJUFbded0dOtPPYb3ZnvwF441TkpI4K3xkh_Aj3CF8XSvpOFbGUCIkTQ-cdk2ly_DX6PI_nO_C7ewtDZZVdTKwDtV0YOiM_4sSrjh7B46OiLYuYDUcflj996iBFN61dO43GRE7d5S9M39bvT4ao67ecjz6dfTz22w4DvkHkUvnG2SCyRcIDg7jFCq7SQAvLbVwgcEgz5UKDO6hOXGqFtoVKuTWKax2HKogLgZ-9BbeliENyMTnvcz0ENqIhQghDX8YybEmNEDzUbfTqVGxrK7zznSq_V9cB3av1mv9sgKN7cLdFrmzQmNp92HHlA9ibtHfzD2GOYWfzgw3sit5gsTFVI61R3LEvRA_rLMPRAdF9sFlD5rpmdArMppQM1I16zw0bqaq6ZGOqFmHD5vLoAM5uYlUfwW65KN0TYEWWOKVUmtEDWKdtWifUkc0yp7SW3IN33QrmpuU0p9YaF3md28RZ3i-2B6970WVD5HGd0EGjhl6kGz-8Mj6ZzZqpfGkLnO6UlrchYJ3_NVgPXvXT6Lx0I6NKt9igDKbfggvJUw8eNzruf0EE9Og4CjyQW9rvBYgYfHumPP9WE4QnEnGj5E___7dewh56UD4-mZ4-g30Egm3t3CHsVquNe45gq9IvarNmkN-wG_0BJAU9eA |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Serum+Adropin+Levels+Are+Reduced+in+Adult+Patients+with+Nonalcoholic+Fatty+Liver+Disease&rft.jtitle=Medical+principles+and+practice&rft.au=Kutlu%2C+Orkide&rft.au=Altun%2C+%C3%96zg%C3%BCr&rft.au=Dikker%2C+Okan&rft.au=Akta%C5%9F%2C+%C5%9Eerife&rft.date=2019-09-01&rft.eissn=1423-0151&rft.volume=28&rft.issue=5&rft.spage=463&rft_id=info:doi/10.1159%2F000500106&rft_id=info%3Apmid%2F30995640&rft.externalDocID=30995640 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1011-7571&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1011-7571&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1011-7571&client=summon |